ReviewTranslational oncology2016
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations.
Review in Translational oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Establishing a Clinically Relevant Radiation Therapy Method for Preclinical Medulloblastoma Research.Advances in radiation oncology · 2026Article
- Biohybrid nanovesicle-mediated targeted delivery of HSP90 inhibitor for enhanced sorafenib therapy of hepatocellular carcinoma after radiofrequency ablation.Materials today. Bio · 2026Article
- Comparative analysis of molecular targeted radiosensitizers in 2D and 3D cancer cell line models.Acta oncologica (Stockholm, Sweden) · 2025Article
- Design, synthesis and antiproliferative activity of novel colchicine derivatives: selective inhibition of melanoma cell proliferation.Frontiers in pharmacology · 2025Article
- How can we establish animal models of HIV-associated lymphoma?Animal models and experimental medicine · 2024Review
- Minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature.International journal of radiation biology · 2024Review
- Minimum Reporting Standards Should be Expected for Preclinical Radiobiology Irradiators and Dosimetry in the Published Literature.Radiation research · 2023Article
- A High Throughput Screen with a Clonogenic Endpoint to Identify Radiation Modulators of Cancer.Radiation research · 2023Article
- The State of Preclinical Modeling for Early Phase Cancer Trials Using Molecularly Targeted Agents with Radiation.Radiation research · 2022Article
- Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR.Biomedicines · 2022Article
- Screening and Validation of Molecular Targeted Radiosensitizers.International journal of radiation oncology, biology, physics · 2021Article
- Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.International journal of radiation oncology, biology, physics · 2021Article
- Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic.International journal of radiation oncology, biology, physics · 2021Article
- ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.Molecular cancer therapeutics · 2021Article
- Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.Molecular cancer therapeutics · 2021Article
- Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care.JNCI cancer spectrum · 2021Article
- Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.Journal of the National Cancer Institute · 2021Review
- Characterization of cardiovascular injury in mice following partial-heart irradiation with clinically relevant dose and fractionation.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Article
- EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.Thoracic cancer · 2020Article
- A Mail Audit Independent Peer Review System for Dosimetry Verification of a Small Animal Irradiator.Radiation research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundClinical testing of new therapeutic interventions requires comprehensive, high-quality preclinical data. Concerns regarding quality of preclinical data have been raised in recent reports. This report examines the data on the interaction of 10 drugs with radiation and provides recommendations for improving the quality, reproducibility, and utility of future studies. The drugs were AZD6244, bortezomib, 17-DMAG, erlotinib, gefitinib, lapatinib, oxaliplatin/Lipoxal, sunitinib (Pfizer, Corporate headquarters, New York, NY), thalidomide, and vorinostat.
methodsIn vitro and in vivo data were tabulated from 125 published papers, including methods, radiation and drug doses, schedules of administration, assays, measures of interaction, presentation and interpretation of data, dosimetry, and conclusions.
resultsIn many instances, the studies contained inadequate or unclear information that would hamper efforts to replicate or intercompare the studies, and that weakened the evidence for designing and conducting clinical trials. The published reports on these drugs showed mixed results on enhancement of radiation response, except for sunitinib, which was ineffective.
conclusionsThere is a need for improved experimental design, execution, and reporting of preclinical testing of agents that are candidates for clinical use in combination with radiation. A checklist is provided for authors and reviewers to ensure that preclinical studies of drug-radiation combinations meet standards of design, execution, and interpretation, and report necessary information to ensure high quality and reproducibility of studies. Improved design, execution, common measures of enhancement, and consistent interpretation of preclinical studies of drug-radiation interactions will provide rational guidance for prioritizing drugs for clinical radiotherapy trials and for the design of such trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.